Explore published research on depression, including study methods and limitations.
Over 15 years, cannabis abusers were four times more likely to develop depression including suicidal thoughts. Depression at baseline did not predict future cannabis abuse, arguing against self-medication.
A 21-year study of 1,265 New Zealand children found cannabis use linked to crime, depression, suicidal behavior, and other drug use, with younger users (14-15) affected more than older users (20-21).
Twin study of 3,360 male pairs finding that the genetic link between depression and cannabis/alcohol dependence was largely explained by shared genetic risk for antisocial personality disorder.
Twin study finding cannabis dependence linked to 2.5-2.9x higher suicide risk even after controlling for shared genetics, while the depression link was explained by shared genetic vulnerability.
Comprehensive review found strong evidence linking cannabis to psychosis, supported the existence of cannabis withdrawal syndrome, and called for more rigorous research on prevention and treatment.
National survey of 43,093 Americans identified five drug abuse patterns, with cannabis-only (5.8%) being the most common and mildest, while polysubstance (0.5%) was linked to the most severe psychiatric profiles.
Study of 119 heavy cannabis users found high rates of depression (46%) and suicidality (42%), predicted by parental alcoholism and childhood adversity rather than cannabis or other drug use.
A clinical trial found that monthly cannabis users responded just as well to combined CBT and medication treatment for anxiety and depression as non-users.
13-year Norwegian study found frequent cannabis use linked to nearly triple the suicide attempt risk but not to depression, suggesting distinct pathways to suicidal behavior.
Ten days of cannabinoid receptor activation produced antidepressant-like effects in male and female rats through the noradrenergic system, but the effect was eliminated by precipitated withdrawal.
In 50,087 Swedish men followed for 33 years, the apparent link between cannabis use and suicide (OR 1.62) was fully explained by pre-existing psychological and behavioral problems (adjusted OR 0.88).
A patient experienced suicidal ideation immediately after cannabis use on two separate occasions, independent of depression or life stressors, suggesting an acute pharmacological trigger in a vulnerable individual.
A systematic review found only 7 RCTs on treating cannabis use in psychosis/depression, with preliminary evidence supporting medication treatment of the primary disorder and longer psychological interventions.
Among 4,075 young French adults, depression (OR ~8) and psychosocial factors predicted suicidal ideation, while cannabis use was not an independent predictor after adjustment.
Brief review linking cannabis use in adolescents to psychosis, depression, panic attacks, and suicidal thoughts.
Cannabis-dependent people with depression had worse social functioning but performed better on some cognitive tests than those without depression.
Endocannabinoid enhancement reduced depression-like behavior during nicotine withdrawal in mice through serotonin 5-HT1A receptor interaction, suggesting combined targeting for smoking cessation.
A new class of chemical compounds can selectively block endocannabinoid-degrading enzymes in the brain, potentially offering pain and mood benefits without full psychoactive effects.
Depression and insight measures distinguished cannabis-induced psychosis from primary psychotic disorders with 97% accuracy in hospitalized patients.
Review found adolescent cannabis use predicts anxiety, depression, and psychosis more strongly than adult use, with earlier initiation increasing risk.
Two-year study of 976 high school students found heavy cannabis use alone predicted depression but not suicidality, while other illicit drug use predicted all three.
Across 22 longitudinal cohorts, cannabis use was linked to about 29 percent higher odds of later depression, with exposure measures often weak and overall bias rated medium.
Population study of 1,560 young adults found lifetime crack cocaine use (2.5% prevalence) was associated with PTSD, antisocial personality disorder, suicide risk, and polysubstance use including cannabis.
Double-blind trial of 52 cannabis-dependent users found escitalopram (SSRI) added to CBT did not improve abstinence rates (19% overall), anxiety, or depression compared to placebo.
In 110 people with early psychosis and cannabis dependence, reducing cannabis was linked to lower anxiety and better functioning, but not to changes in core psychotic symptoms.
Canadian national survey found 3.9% past-year depression prevalence, with about 5% of depressed individuals also having cannabis use disorders. 63% sought treatment but 38% perceived stigma.
Among nearly 30,000 adults over 50, marijuana-only users had 1.5x higher odds of depression vs. non-users, though they fared better than users of other illicit drugs.
Mouse study shows a CB1 receptor blocker produced antidepressant effects that were mediated through the opioid system, revealing a mechanistic link between cannabinoid and opioid pathways in depression.
In identical twin pairs, the twin who used cannabis frequently was about twice as likely to have depression and 2.5 times as likely to report suicidal thoughts, even after controlling for shared genetics.
Survey of 47 Parkinson's patients found large self-reported improvements in falls, pain, and tremor with medical cannabis, but 17% experienced confusion or hallucinations.
Nearly half of 2,774 cannabis users reported substituting cannabis for prescription drugs — opioids, benzodiazepines, and antidepressants most commonly replaced. Medical users were 5x more likely to substitute.
Narrative review finding substantial evidence linking cannabis to psychosis and other drug use, mixed evidence for depression and anxiety, with adolescent onset carrying the greatest psychiatric risk.
Study of 302 adults finding that reducing cannabis use over 12 weeks improved anxiety, depression, and sleep quality but not overall quality of life, with effects independent of other substance use changes.
Rat study showing a dual FAAH inhibitor/TRPV1 blocker produced antidepressant effects at a specific dose by enhancing anandamide signaling through CB1 receptors while blocking the opposing TRPV1 pathway.
Screening of 22,095 primary care patients in Washington State finding 15.3% past-year cannabis use and 3.1% daily use, with rates reaching 36% among young adults and 32% among young men with depression.
Rat study showing two hemoglobin-derived peptides had opposite effects on the endocannabinoid system: hemopressin caused anxiety and depression-like behavior while RVD-hemopressin produced anti-anxiety and antidepressant effects.
Longitudinal study of 158 young men finding escalating adolescent cannabis use disrupted reward-prefrontal brain connectivity, predicting more depression, anhedonia, and lower education at age 22.
The biology linking the endocannabinoid system to PTSD was strong, but clinical evidence for cannabis as treatment was weak. Nabilone showed real promise for nightmares specifically.
Over 12 months, depressed outpatients who used marijuana non-medically showed less improvement in depression and suicidal ideation and attended fewer psychiatry visits.
Boosting endocannabinoid levels with a FAAH inhibitor reversed depressive behavior, restored synaptic plasticity, and rescued neurogenesis damaged by adolescent THC in female rats.
Overview found cannabinoids produce dose-dependent acute effects on anxiety, mood, and cognition, with chronic use linked to tolerance, dependence, withdrawal, and associations with psychiatric disorders.
Israeli survey of 383 fibromyalgia patients found 84% used cannabis with 94% reporting pain relief, though only 44% were medically licensed and most smoked rather than using other methods.
A review found the endocannabinoid system may contribute to bipolar disorder pathophysiology, with CB2 receptor activation emerging as a potential mood-stabilizing target, though evidence remains limited.
A Lancet meta-analysis of 83 studies found scarce evidence that cannabinoids help depression, anxiety, PTSD, or other mental disorders, with THC products doubling adverse event rates versus placebo.
Adolescent cannabis smoke and THC exposure in rats produced no lasting anxiety, depression, or cognitive effects in adulthood, suggesting human associations may involve non-cannabinoid factors.
Past-year marijuana use nearly doubled among former US cigarette smokers from 2002-2016, while depression and binge drinking also rose, threatening sustained smoking cessation.
Mouse study shows depression-induced pain amplification involves changes in brain endocannabinoid levels, and locally boosting endocannabinoids reduced the heightened pain response only in depressed animals.
Study of 5,622 Canadian youth found depression, anxiety, and drug disorders linked to being out of school and work, but cannabis use disorder showed no association at all.
Meta-analysis of 23,317 individuals found adolescent cannabis use linked to 37% higher depression risk and 3.46x higher suicide attempt risk in young adulthood, even after accounting for pre-existing mental health.
Canadian study of 43,466 people found women who use cannabis regularly experience significantly more psychological distress and suicidal thoughts than men who use at the same frequency.
Study of 401 at-risk teens found 74% maintained low cannabis use, with boys more likely to show chronic or escalating patterns and conduct disorder showing the strongest bidirectional link to problematic use.
Case report of CBD use for chronic pain and mood disorder in neurofibromatosis type 1, suggesting potential but requiring controlled trials for validation.
Study of 1,661 Australian teens found 10% used multiple substances, with depression, conduct problems, and school environment as the strongest predictors, suggesting prevention should target mental health.
Depression-model rats showed reduced endocannabinoid signaling with notable hemisphere-specific differences in prefrontal cortex and hippocampus.
Review finds limited support for cannabis benefits in mental illness, growing evidence of harm in psychosis and mood disorders, and proposes a framework for understanding addiction vulnerability.
Young adults with both marijuana use and depression had worse verbal memory and thinner cortex than those with either condition alone, suggesting additive harm.
A longitudinal study of 1,606 Quebec adolescents found depression predicted subsequent weekly cannabis use, while the link between cannabis and suicidal ideation was fully explained by other substance use.
A review found suggestive evidence that CBD may reduce anxiety and fear responses in PTSD, but cannabis use may worsen depression. Well-designed randomized trials remain largely absent across these conditions.
Prospective study of 214 first-episode psychosis patients found continued cannabis use was associated with increased depression in those with high insight and medication adherence after one year.
Review examines the theoretical basis for combining cannabis terpenes with cannabinoids to treat mood and anxiety disorders, finding preclinical support but limited clinical evidence.
Ontario study found frequent cannabis use in youth aged 12-17 was associated with elevated anxiety, depression, and behavioral symptoms, with associations 2-3 times stronger in girls than boys.
National survey of nearly 88,000 adolescents found cannabis use linked to higher depression and suicide attempts, but the relationship between use frequency and depression was unexpectedly non-linear.
Canadian survey data shows the association between monthly cannabis use and depression/suicidal ideation strengthened from 2002 to 2012, with monthly users in 2012 having ~1.5 times the odds of both outcomes vs 2002 users.
Systematic review of 23 studies found CBD most promising for anxiety and as adjunct treatment for psychosis, with limited evidence for depression and PTSD.
Canadian national survey of 24,089 people found cannabis use was associated with a weaker link between PTSD and both severe depression and suicidal ideation.
Study of 431 chronic pain patients found emotion dysregulation explained the link between cannabis use problems and anxiety, depression, and suicidal ideation.
Mouse study found cannabinoid receptor compounds enhanced antidepressant effects of tianeptine and agomelatine without changing brain drug levels, suggesting true synergy.
Mouse study found both CB2 agonist and inverse agonist enhanced three classes of conventional antidepressants without changing brain drug levels.
Analysis of 410,138 NSDUH respondents found cannabis exposure tracked with all four mental health indices, with serious mental illness doubling as use increased and legalization linked to 12.91% attributable fraction.
Mouse study found CBD produced antidepressant effects by normalizing stress-induced DNA methylation changes in prefrontal cortex and hippocampus.
Postmortem study found CB1 receptors 20% elevated in prefrontal cortex of people with major depression, with unchanged CB2 and increased mTOR activity.
First clinically-focused systematic review found CBD tentatively supported for social anxiety and adjunctive schizophrenia, with high-THC showing no depression benefit.
A secondary analysis of 302 adults in a cannabis cessation trial found that depression predicted less abstinence (especially in women) and that depressive symptoms preceded increased cannabis use, not the other way around.
Terpineol reduced depressive-like behavior in an inflammatory mouse model, with effects mediated through CB1, CB2 cannabinoid receptors and D2 dopamine receptors.
Seven days of high-dose CBD produced antidepressant-like effects in mice by increasing hippocampal serotonin and noradrenaline, the same neurotransmitters targeted by conventional antidepressants.
URB597, which boosts natural endocannabinoids, prevented anxiety and depression in mice during methamphetamine withdrawal through CB1, CB2, and TRPV1 receptor pathways.
Pilot study of 17 burning mouth syndrome patients found cannabis oil improved pain, anxiety, and depression over 4 weeks, with benefits lasting through 24-week follow-up.
Analysis of 281,650 young adults found cannabis use disorder was associated with higher suicidality regardless of depression, with women showing significantly stronger associations than men.
Case report of a teenager with multiple substance addictions and depression who improved across all domains after switching from antidepressants to CBD, including quitting all illegal drugs.
A study of 604 pregnant women found continued cannabis use was associated with higher anxiety and depression scores, and women with more depression symptoms were nearly 3 times more likely to keep using rather than quit.
A study of 605 young adolescents (mean age 13) found cannabis users scored much higher on hopelessness, depression, and anomalous reality perception, with hopelessness being the strongest unique predictor of use.
CBD prevented anxiety, memory loss, and depressive behavior after brain ischemia in mice, working through four different receptor systems including CB1, CB2, serotonin, and PPAR-gamma.
An fMRI study of 74 young adults found that depression and cannabis use each independently altered brain activation during emotion regulation, but in different temporal lobe regions.
Meta-analysis of 8 national surveys finds cannabis use disorder is associated with 3x higher odds of major depression and generalized anxiety disorder.
Real-world study of 279 patients finds CBD-rich treatment significantly improves pain, anxiety, and depression at 3 months, but only in those with moderate-to-severe symptoms.
Systematic review found only 8 small RCTs testing cannabinoids for depression, anxiety, or PTSD, with insufficient evidence to recommend cannabis for any of these conditions.
PK modeling and adverse event data show cannabis and CBD can increase escitalopram and sertraline levels in adolescents, raising the risk of side effects like dizziness and fatigue.
NHANES data from over 21,000 adults linked past-30-day cannabis use to 54% higher odds of suicidal ideation and 53% higher odds of depression.
Low-THC broad-spectrum cannabis oil reversed pain, thermal sensitivity, and depression in a mouse fibromyalgia model at doses as low as 0.1 mg/kg.
Survey of 1,230 veterans found those who co-used tobacco and cannabis had significantly higher stress, PTSD, depression, and anxiety than single-substance users.
Meta-analysis of 20 studies found cannabis use was associated with 2.3x risk of suicide attempt, 2.0x suicidal ideation, and 1.7x suicide planning among youth ages 11-21.
Pilot study showed CBT for insomnia resolved sleep problems in cannabis users, with 80% reducing cannabis use at 3 months and sustained improvements in mood.
Canadian survey during COVID-19 found increased cannabis use was associated with nearly twice the odds of suicidal ideation, alongside social isolation and depression.
Review argues antidepressants are likely less effective in cannabis-using teens, based on overlapping neurochemical pathways, but no clinical trials have tested this directly.
Among 608 US veterans with PTSD, frequent cannabis users were 3-4x more likely to have depression, anxiety, and suicidal ideation, and 8-12x more likely to rely on avoidance coping.
Young adults with bipolar disorder showed a unique brain response to stress that correlated with less cannabis use and better depression outcomes over one year.
Cross-referencing cannabis methylation studies with depression genetics found multiple depression-associated genes are epigenetically regulated by cannabis, suggesting a molecular mechanism for the cannabis-depression link.
In a cannabis dependence trial, depression, anxiety, insomnia, and pain all improved over 12 weeks regardless of medication type, and even without complete abstinence from cannabis.
Review confirmed gender differences exist in cannabis-related psychosis, depression, and anxiety, but the direction varies. Women may be more vulnerable to mood effects; men may show stronger psychosis links.
JAMA Psychiatry study found bipolar II and cannabis use disorder cluster in families. Mood episodes typically preceded CUD, suggesting shared vulnerability and a potential prevention target.
In vitro testing found higher CBD concentrations increased some inflammatory markers in blood from depressed patients, challenging the assumption that CBD is uniformly anti-inflammatory.
Systematic review of 6 studies found contingency management effectively reduced cannabis use and achieved abstinence periods in people with psychotic disorders or major depression.
First CBG patient survey found users reported it effective for anxiety (51%), pain (41%), and depression (33%), with 74-80% rating it superior to conventional medications and 44% reporting no side effects.
Longitudinal study of 1,465 young people found cannabis use and suicidal ideation were reciprocally linked from ages 15-20, suggesting they may reinforce each other over time.
Saskatchewan pandemic survey found suicidal ideation was highest (25.8%) among those with both cannabis and alcohol problems, with younger adults and LGBTQIA2S+ individuals at elevated risk.
MASCC systematic review of 15 RCTs found no high-quality evidence for cannabis treating anxiety, depression, or insomnia in cancer, though sleep showed some promise.
Women increasingly use cannabis for endometriosis, pelvic pain, and period cramps, with retrospective data suggesting benefit — but clinical trials are nearly nonexistent and barriers to medical access persist.
12-month study of 323 fibromyalgia patients found medical cannabis reduced pain partly through improvements in sleep and anxiety/depression symptoms.
Rome police seizures show hashish THC nearly doubled from 13.7% to 27.1% in seven years, with some samples exceeding 40% — and young males are the primary users.
Propensity-matched study found medical cannabis authorization associated with increased ED visits and hospitalization for depressive disorders.
Four-year study of 3,085 college-age adults found depressive symptoms predicted cannabis vaping initiation, with rates doubling from 2017 to 2019.
Among 945 depressed/suicidal youth, 12.7% showed high use of all substances and had the most ADHD, substance use disorders, and suicidality, while 23.8% showed moderate alcohol/nicotine/cannabis use.
Longitudinal study of 381 people found weekly childhood cannabis use and depression independently accelerated DNA methylation aging from adolescence to adulthood, with combined effects equivalent to 3-4 extra years of biological aging.
JAMA study of 504 pregnant women found nearly half used cannabis, with 58% citing mental health reasons. Those using for mental health had the worst depression scores but no faster improvement than non-users across pregnancy.
In adolescent rats, THC exposure caused lasting anxiety and depression-like behaviors linked to brain changes in the nucleus accumbens. The antioxidant NAC prevented all of these effects.
Population study of 910 adults 65+ found 20% had used marijuana and 5% used recently — current users showed more depression, anxiety, and functional impairment.
In a prospective study of 545 young women of color, frequent cannabis use (20+ times monthly) predicted increased depression, delinquency, and school suspension over 6-12 months.
Among 5,281 Americans aged 13-40, co-use of tobacco and cannabis was linked to higher depression rates than either substance alone, with e-cigarettes plus smoked cannabis the most common combination among depressed co-users.
Norwegian 13-year longitudinal study of 1,988 youth found within-person cannabis use increases linked to anxiety, depression (males), and suicidal ideation (3.4x in males, 2.5x in females).
A study of 1,618 trauma-exposed civilians found that heavy cannabis and alcohol users had worse PTSD and depression symptoms, with all groups peaking at 8 weeks posttrauma.
Survey of 550 opioid addiction patients found 23% use CBD — primarily for anxiety, pain, and sleep, with 42% using it specifically for withdrawal relief.
A study of 799 pregnant patients found prenatal cannabis use was associated with 60% higher postpartum depression risk, rising to 62% in those with a history of depression.
Among 360 Swiss cannabis users, depression and ADHD specifically predicted heavier use after controlling for other factors, while anxiety and psychosis associations disappeared.
A mouse model of high-dose prenatal THC exposure found offspring developed anxiety, depression, cognitive problems, and increased alcohol preference, with sex-dependent effects.
Systematic review of 78 studies found cannabis use associated with increased depressive and manic symptoms, higher risk of developing mood disorders, and worse treatment outcomes.
Among 12- to 15-year-olds in the ABCD Study, cannabis use was linked to more depression symptoms, with the strongest association in teens who also had smaller amygdala volumes.
A very low dose of CBD (1 mg/kg) partially reversed stress-induced behavioral changes in mice and completely restored mature synapse formation in the prefrontal cortex.
A study of over 2 million pregnant patients found cannabis use associated with 2.7x higher depression, 5.5x higher panic disorder, 10.7x higher suicidal ideation, and 13.6x higher alcohol abuse, though confounding by underlying risk factors is likely.
Protocol for a 200-teen RCT testing whether 8 weeks of cannabis abstinence reduces depression and suicidal ideation — using 8 daily phone surveys to capture the moment-by-moment relationship.
Depression was associated with 30% higher odds of frequent cannabis use among Black college students.
Review maps bidirectional interactions between endocannabinoids and nine neuropeptide systems in the brain, revealing complex regulatory networks relevant to depression and anxiety treatment.
Tracked 2,762 college students over a year and found anxiety predicted later hazardous cannabis use, with impulsivity traits amplifying the connection.
Two-year study of 961 emerging adults found negative cannabis consequences predicted later depression more than depression predicted cannabis use, especially in women.
Survey of 367 college students found monthly simultaneous cannabis and alcohol use predicted depression in both sexes, with possible male-specific links to anxiety and stress.
Systematic review found depression and cannabis use share brain reward processing regions but no consistent biomarkers, with cannabis amotivation vastly understudied (only 2 studies).
A German survey of 702 CBD users found 38% self-medicate for sleep, pain, depression, and anxiety, with older and unemployed individuals most likely.
A 10-year study of 3,299 people with HIV found 26% were consistently high cannabis users, associated with depression, tobacco use, and older age.
CBD reduced depression-like symptoms and protected memory in socially isolated mice, but unexpectedly increased anxiety in non-stressed mice, highlighting CBD's context-dependent effects.
A study of nearly 3,800 medical cannabis patients found 25% had suicidal thoughts at treatment entry, with rates declining over 12 months, though the observational design limits causal conclusions.
A genetic study found social isolation causally increases cannabis use disorder risk by over 4-fold, with depression acting as a key mediator explaining about 22% of the effect.
A meta-analysis of 25 studies found cannabis use linked to suicidal thoughts (46-78% higher odds) and attempts (117% higher in teens) even after accounting for depression, though depression partly explains the connection.
Randomized study found CBD reduced depression, anxiety, and stress more than THC over 4 weeks in underrepresented groups, with perceived discrimination amplifying the benefit.
CBD given during repeated social stress in mice prevented social avoidance and enhanced cocaine vulnerability while normalizing serotonin, endocannabinoid, and stress hormone gene expression.
Study of 257 women found cannabis use during pregnancy independently predicted higher postpartum PTSD and depression, separate from the effects of intimate partner violence.
Survey of 544 SUD treatment patients found cannabis use linked to more trauma and psychiatric diagnoses, but trauma may explain the cannabis-mental health connection.
A review of 55 studies found drug legalization and decriminalization had mostly neutral effects on population-level mental health outcomes including depression, anxiety, and psychosis.
Over a third of Irish drug users tried HHC before its 2025 ban, with 90% reporting negative effects—a cautionary tale about legal synthetic cannabinoid alternatives.
An ABCD Study of nearly 10,000 adolescents found that cyberbullying victims were 4.65 times more likely to try cannabis within the next year, alongside increased risks for depression and suicidal behavior.
A study of 93,743 US adults found that cannabis use mediated a larger share of the link between depression, pain, and suicidal behavior in women than in men.
A study of 153 teens with mood symptoms found that cannabis users reported worse anticipatory anhedonia, with more frequent use linked to greater difficulty looking forward to pleasurable experiences.
A study of 167,504 teens found five substance use patterns, including a cannabis-centered class, and all groups had higher rates of depression, suicidal ideation, and violence than non-using peers.
Large prospective study found ongoing cannabis use beyond the first trimester was linked to 60% higher odds of depressive symptoms later in pregnancy, while any-use overall was not significant.
Among 1,962 cancer patients, higher CBD doses and swallowed products were associated with the best anxiety improvement—while depression responded mainly to how cannabis was taken.
Monthly monitoring of 772 young adults for 2 years found those who consistently used more cannabis during depressive episodes developed more hazardous use by 30-month follow-up.
Full-spectrum CBD reversed inflammation-induced depression in rats while CBD isolate did not, providing direct evidence for the "entourage effect" in mood disorders.
A review of 60 studies mapped psychosis development: early symptoms are mostly depression and anxiety, with cannabis conferring 4-fold risk (10-fold with genetic vulnerability).
Patients who continued cannabis after first psychotic episode had dramatically worse depression, 3x higher relapse rates, persistent suicidality, and no functional improvement over 9 months.
Analysis of 1,599 Black male college students found recent marijuana use associated with 77% higher odds of moderately severe to severe depression, compounded by financial stress and racial discrimination.
Annals of Internal Medicine review of 99 studies (221K participants) finds high-THC cannabis consistently associated with psychosis and addiction, with mixed results for anxiety and depression depending on therapeutic context.
Narrative review proposes the endocannabinoid system as a unifying mechanism behind diverse treatments for treatment-resistant depression, from brain stimulation to psychedelics.
Study of 80 adults with depression found higher physical fitness associated with lower resting plasma endocannabinoid levels, suggesting a more regulated system.
CBD reduced depressive behaviors and brain inflammation in female rats exposed to both obesity and chronic stress, with effects depending on the type of stressor.
Review explains why cannabis-mental health findings seem contradictory: it depends on THC vs CBD content, use frequency, age, genetics, and other often-overlooked factors.
Study of 195 Colorado cannabis users found frequent use associated with higher anxiety but not depression, with similar rates of prescription medication use across all groups.
In young cannabis users, plasma THC metabolite concentration was the only measure — over self-report, urine, hair, or oral fluid — that predicted depression symptoms, suggesting blood testing may reveal hidden clinical risks.
Machine learning identified two endocannabinoid-related genes with reduced expression in depression patients, validated as potential diagnostic biomarkers with a predictive nomogram for MDD risk.
Prospective cohort study finding that new medical cannabis patients with anxiety and depression showed improvements over 6 months using real-time symptom monitoring.
Analysis of 150,992 college students showing organized sports participation moderates the link between cannabis use and depression, anxiety, and PTSD diagnoses.
NHANES analysis showing cannabis doubles depression odds, with 11-17% of the effect mediated by combustion-related pollutants (PAHs), suggesting smoking method matters.
Preclinical study showing chronic stress reduces endocannabinoid CB1 receptors in the ovBNST brain region, causing depression that is partially rescued by enhancing endocannabinoid signaling.
Among 353 older adults with chronic pain, the small minority using cannabis had more pain interference and depression over time—though the tiny sample size limits conclusions.
Among 616 Mexican American college students who'd never used cannabis, depressive symptoms predicted starting cannabis a year later—family factors didn't buffer it.
Rat study shows combining a CB1 cannabinoid receptor agonist with capsaicin produces synergistic antidepressant-like effects through complementary gut-brain pathways.
National survey of nearly 70,000 U.S. teens found THC vaping linked to depression while CBD-only vaping was associated with higher anxiety symptoms — a surprising finding that challenges simple narratives.
Scoping review of RCTs found thin and mixed evidence for cannabis treating mental health conditions — CBD shows some anxiety promise but most psychiatric evidence remains inconclusive.
87-day daily diary study of 74 veterans found cannabis predicted less next-day depression for veterans without PTSD, but this mood benefit disappeared in veterans with PTSD — complicating the self-medication narrative.
A longitudinal study of 1,745 adults found that attachment anxiety amplifies the link between cannabis use and depression, with the combination of high anxiety and avoidance predicting the greatest depressive increases.
Analysis of 35,585 adults with chronic conditions found that co-use of marijuana and opioids carried the highest depression risk (nearly 2x odds), exceeding either substance used alone.
Canadian national survey data shows the cannabis-mental health association roughly doubled from 2012 to 2022, with frequent users showing up to 5.4x higher suicidality prevalence by 2022.
UK registry study of 698 medical cannabis patients with depression shows sustained improvements in depression, anxiety, sleep, and quality of life over 24 months, with 91% experiencing no adverse events.
Brain imaging study of 395 people shows cannabis users have more efficient brain networks, but co-occurring depression weakens these effects, revealing a complex neurobiological interaction.
Network analysis reveals alcohol problems link uniquely to anxiety and suicidal thoughts while cannabis problems link to mania and dissociation, with patterns stable across ages 16-81.
Over a decade, the teen cannabis-distress link grew stronger, especially for frequent female users, while overall teen use declined.
A 12-week virtual group therapy program reduced cannabis use, cravings, depression, and anxiety with 68% retention.
Systematic review of 38 studies finds integrated CBT works for CUD with co-occurring conditions, and AI tools can enhance contingency management.
Review mapped how cannabinoids interfere with drug metabolism through CYP450 enzymes, potentially altering effectiveness of antidepressants, blood thinners, opioids, and more.
A study of nearly 93,000 Canadians over five years found cannabis use after legalization increased mainly among those without mental health problems, with people reporting anxiety, depression, bipolar disorder, PTSD, or schizophrenia showing few changes in use.
A meta-analysis of 36 studies found youth cannabis users aged 15-30 had 28% higher adjusted odds of depression, 58% higher odds of anxiety, 65% higher adjusted odds of suicidal ideation, and 80% higher adjusted odds of suicide attempts.
Two samples of veterans (N=741 total) showed that cannabis use didn't undermine intensive PTSD treatment — users and non-users improved similarly.
Canadian 24-week study found medical cannabis patients improved on pain, anxiety, depression, and quality of life measures, but improvements fell below clinically meaningful thresholds.
Large Kaiser study found adolescent cannabis use associated with significantly higher rates of psychotic, bipolar, depressive, and anxiety disorders diagnosed through age 25.
German health insurance data from 4 million youth showed cannabis-related diagnoses rose 22% (2013-2022), with 78% having co-occurring psychiatric disorders, especially depression.
CBD reversed depression-like behavior in mice by restoring mitochondrial function, reducing oxidative stress, and decreasing neuroinflammation in the hippocampus.